Enhance Early Biomarker Discovery: Translating In Vitro and In Vivo Multi-Omics Oncology Data

Unlock the power of multi-omics data to revolutionize early biomarker discovery in oncology drug development.

In this webinar, the expert speaker will explore the critical role of early biomarker identification in de-risking drug candidates and increasing clinical success rates. As the landscape of preclinical oncology evolves, integrating comprehensive multi-omics analysis with advanced in vitro and in vivo screening models has become essential for generating translatable and actionable insights.

The speaker will delve into the intricate process of leveraging diverse oncology models from traditional cell lines to innovative organoids and patient-derived xenografts (PDX). She will provide valuable guidance on how these advanced patient models can yield deeper insights into precision medicine approaches, drug resistance mechanisms and effective combination therapies. By harnessing the complete potential of multi-omics data, researchers can make informed decisions that align treatments with patient responses.

Throughout the session, she will address the challenges and opportunities in translating complex multi-omics data into meaningful biomarker discoveries. Attendees will learn about state-of-the-art in silico techniques that help decipher the vast amounts of information generated from these studies, enabling them to identify the most promising biomarkers for additional investigation. Do not miss this opportunity to stay at the forefront of oncology drug development.

Register for this webinar to learn how to harness the full potential of multi-omics data and advanced patient models to drive early biomarker discovery.

Keywords: Cancer, Drug Development, Patient Data, Clinical Research, CRO, Oncology, Biomarkers, Cancer Research, Clinical Data, Data Management, Clinical Data Management, Data Science, Sites

Others Details

Life Sciences,Pharmaceutical,Drug Discovery & Development,Biomarkers